🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Look, cagri-sema is probably not enough weight loss, but the bigger problem is that it’s not better in any dimension that really matters - tolerability, durability, or ease of weight loss… bloomberg.com/news/articles/…

Medications like #Ozempic, while great in helping with #weightloss, are often considered a quick solution, but they take months to achieve full effects and most people stop taking them soon after starting. At Fractyl Health, we are helping to break the pattern of chronic

Modern pharmacotherapy may be efficacious. However, adherence to treatment is low

“adherence needs to be managed”

Join our earnings call on Monday, March 3 as we look back at 2024 and share what’s next for Fractyl Health. #NASDAQ: $GUTS #FractylForward

🚨 #ECO2025 this past weekend reveals a critical gap: rapid weight regain post-GLP-1RA cessation threatens lasting obesity solutions. Telling people they need to stay on medical therapy to manage their weight for the rest of their lives is not going to work. At Fractyl Health,

Couldn’t agree more. Making America Healthy Again means reducing intake of unhealthy foods, exercising more, and fixing the root cause biology in the body causing the disease. Chronic medication cannot solve this problem for us.

“Hey, look at root causes,” says Dr Makary

Uh oh

model says tirzepatide is cost-effective but only by assuming: 📌 5 years of perfect adherence 📌 Benefits persist long after stopping- not proven 📌 Discounted drug prices (not what payers actually pay) 📌 A 30y time horizon Real-world? Much less certain

What we need is a reliable off ramp

Will initial use of GLP-1 medicines serve as a portal for endoscopic and surgical approaches to maintain #weightloss nature.com/articles/d4158… Nature News & Views Elie Dolgin

Simple but huge problem: How to keep weight off after obesity drugs…our work ⁦Fractyl Health⁩ with #Revita featured nature.com/articles/d4158…

Positive REVEAL-1 Post-GLP Weight Maintenance Data Update This morning we announced an exciting data update from our REVEAL-1 Cohort study on post-GLP-1 weight maintenance. In this interim analysis, 13 participants across several centers in the United States were followed for 3

Yet another study showing high discontinuation rate of both semaglutide and tirzepatide up to 50% at 1 year in the real world. Top discontinuation reasons included: • Side effects (36%) • Logistical challenges (24%) • Cost (23%) • Shortages (11%) • Inadequate weight loss

People gain more weight after stopping GLP-1s than they had lost in the first place - from a new study. Revita for post-GLP-1 weight maintenance may be the most important clinical trial in obesity today…randomized data from REMAIN-1 coming later this quarter…

“Sixth sense” in your gut that controls weight and metabolism - studyfinds.org/scientists-dis…

An often overlooked concern about “access” to GLP-1s is the ongoing uncertainty associated with perpetual access even for those who are insured. Sometimes it’s just easier to get rid of the problem altogether (as with bariatric surgery). Who can blame this patient for frustration